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Research
Beginning early in sex determination and
gonadogenesis in ﬁsh, communication between
nonadjacent tissues is necessary. This commu-
nication is accomplished through the endocrine
system, which controls sex differentiation
through complex interactions between the cen-
tral nervous system and gonads using pituitary-
derived gonadotropins and sex steroids
produced in the gonad and brain (Nagahama
1994). Production of these sex steroids is very
strongly linked with the early steps of gonadal
differentiation, and they can influence long-
term sex determination choices (Devlin and
Nagahama 2002). Further, it has been demon-
strated that exposure to estrogen or estrogen-
mimicking chemicals during a critical period of
development can result in genotypic XY males
developing into fully functional phenotypic
females, whereas exposure of genotypic XX
females to androgenic chemicals can result in
development of phenotypic males (Cheek et al.
2001a, 2001b; Edmunds et al. 2000; Gronen
et al. 1999; Hunter and Donaldson 1983;
Yamamoto 1969).
Because of the critical role of estrogen in
the very early stages of sex determination and
sex differentiation, the estrogen-synthesizing
enzyme is of likely importance. As in all verte-
brates, in fish this function is performed by
cytochrome P450 aromatase, which converts
androgens to estrogens and is expressed in a
number of tissues, including the brain, liver,
and gonads. Recently, a second isoform of aro-
matase (cyp19b; Genbank accession no.
AY319970; National Center for Biotechnology
Information, National Library of Medicine,
Bethesda, MD) has been found in the brain
of several teleost species (Callard and
Tchoudakova 1997; Chiang et al. 2001; Kuhl
et al. 2005). This isoform has much higher
activity and mRNA levels in the brain than
the ovary has of ovarian aromatase (Kishida
and Callard 2001).
It has been hypothesized that altered
expression of aromatase is important in
environmentally inﬂuenced sex differentiation.
Increases in brain aromatase expression occur
in 0- to 14-day-posthatch (dph) medaka con-
comitantly with xenoestrogen-induced femi-
nization (Kuhl et al. 2005), whereas ovarian
aromatase mRNA transcripts at this life stage
are not detectable. Conversely, inhibition of
aromatase activity can result in masculinization
of genotypic females (Piferrer et al. 1994).
Whether altered aromatase activity is directly
responsible for sex reversal is not known. In
the present study we aimed to further examine
the critical role aromatase plays in the genesis
of developmental abnormalities in response to
endocrine disruptors.
Most research to date on the effects of
endocrine-disrupting chemicals (EDCs) has
focused on abnormalities induced by exposure
to a single compound. However, in the envi-
ronment, humans and wildlife are exposed to
diverse mixtures of androgenic, estrogenic,
antiandrogenic, and antiestrogenic compounds
(Bush et al. 1990). Only recently has focus
begun to shift to examining the impact of mix-
tures of EDCs on human and wildlife popula-
tions. Most of this research, however, has
focused on the synergism between several weak
estrogenic compounds (Bergeron et al. 1999;
Payne et al. 2000). These studies demonstrate
that there is an additive effect of several weakly
estrogenic EDCs. To date, little work has been
done on the impacts of mixtures of antagonistic
EDCs. It is unknown if an androgenic or anti-
estrogenic chemical can block the activity of an
estrogenic one. Here we address this question
by examining if xenoestrogen [dichloro-
diphenyltrichloroethane (o,p´-DDT)]-induced
feminization of developing medaka can be pre-
vented by coexposure to a pharmaceutical
[fadrozole (FAD)] and an environmental aro-
matase inhibitor (AI), tributyltin (TBT). We
hypothesize that o,p´-DDT activates the estro-
gen receptor to induce transcription of brain
aromatase. Increased brain aromatase activity
results in increased estradiol levels feminizing
the development of the fish. We further
hypothesize that inhibiting aromatase activity
will prevent a xenoestrogen-induced surge of
estradiol production and prevent feminization.
o,p´-DDT is a known xenoestrogen that
can negatively affect reproduction and
development in ﬁsh, through immersion expo-
sure (Cheek et al. 2001a, 2001b) and direct
injection into oocytes (Edmunds et al. 2000).
FAD has been used extensively in breast cancer
research as a pharmaceutical inhibitor of aro-
matase and has been shown to be a reversible
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In fish, exposure to estrogen or estrogen-mimicking chemicals (xenoestrogens) during a critical
period of development can irreversibly invert sex differentiation. In medaka, a male-to-female
reversal upon exposure to a xenoestrogen is accompanied by an increase in brain aromatase expres-
sion and activity. However, whether this increase is the direct cause of sex reversal is unknown. In
this study we further examined the role brain aromatase plays in genesis of developmental abnor-
malities in response to endocrine-disrupting chemicals (EDCs). Further, the effects of a mixture of
apparent antagonistic environmentally relevant EDCs on development were examined to deter-
mine if their combined actions could lessen each other’s impacts. To this end, hatchling medaka
were subjected in a 2-week flow-through immersion exposure to an estrogen mimic
[dichlorodiphenyltrichloroethane (o,p´-DDT)] and to pharmaceutical [fadrozole (FAD)] and envi-
ronmental aromatase inhibitors [tributyltin (TBT)] alone and in combination. Brain aromatase
expression and enzyme activity were measured on exposure days 5, 9, and 14 by real-time reverse-
transcriptase polymerase chain reaction and tritiated water release assay, respectively. We recorded
sex reversals at sexual maturity by examining the phenotypic and genotypic sex of d-rR–strain
medaka. Results indicate that FAD and TBT inhibit aromatase activity in o,p´-DDT–treated ﬁsh
but do not prevent feminization, indicating that increased brain aromatase activity is not critical
to EDC-induced male-to-female sex inversion. The observation that estradiol biosynthesis
inhibitors do not block the effect of the xenoestrogen suggests that in the environment, exposure
to seemingly antagonistic EDCs does not necessarily lessen the harmful impacts of these com-
pounds. Key words: brain aromatase, fadrozole, medaka, o,p´-DDT, sex differentiation, sex rever-
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http://dx.doi.org/ [Online 27 October 2005]competitive inhibitor of aromatase in birds
(Elbrecht and Smith 1992), mammals (Steele
et al. 1987), and fish (Afonso et al. 1999,
2001). In Nile tilapia (Oreochromis niloticus),
the suppression of aromatase with a FAD-
treated diet resulted in a 100% male popula-
tion Afonso 2001; Kwon et al. 2000). TBT
has been used as an antifouling biocide in
paint for boats, for wood treatment and
preservation, and as a fungicide/bactericide in
textile and industrial water systems (Gehring
et al. 1991). At very low concentrations, TBT
can disrupt the endocrine system, as evidenced
by the induction of male sexual characteristics
in female gastropods (Oberdorster and
McClellan-Green 2002; Smith 1981). TBT
has also been shown to be an EDC in ﬁsh, as
well. A 30-day exposure to 100 ng/L TBT in
zebrafish (Danio rerio) resulted in an almost
completely male population (McAllister and
Kime 2003). It is hypothesized that TBT acts
as a competitive inhibitor of aromatase, which
causes accumulation of testosterone and mas-
culinization of the organism (McAllister and
Kime 2003; Oberdorster and McClellan-Green
2002).
Our results from the present study demon-
strate that an increase in aromatase activity is
not needed for EDC-induced feminization and
that antiestrogenic AIs are unable to prevent
xenoestrogen-induced feminization.
Materials and Methods
Experimental animals. Medaka (d-rR strain)
used in this study were hatched from brood-
stock cultured and maintained at the Gulf
Coast Research Laboratory, University of
Southern Mississippi (Ocean Springs, MS).
The d-rR strain contains a Y-chromosome–
linked gene coding for a red body color pheno-
type, allowing for the simple determination of
sex genotype: males have red phenotype, and
females have white. Medaka also have sec-
ondary sex characteristics that are reﬂective of
sexual phenotype. Females have shorter anal
ﬁns, and males have a notched dorsal ﬁn. With
the d-rR strain and secondary sex characteris-
tics (fin morphology), sex reversals can be
determined by simple observation of body
color and fin development. Animal care and
experimentation were conducted in accordance
with University of Southern Mississippi guide-
lines for animal care and use, and animals were
treated humanely with regard for alleviation of
suffering. Broodstock cultures were maintained
in 300-L ﬁberglass runs at a 27 ± 1°C. A 16-hr
light/8-hr dark photoperiod was provided by
timer-controlled overhead fluorescent lights.
Broodstock cultures were fed a minimum of
twice daily, one feeding of commercial flake
(Ziegler Brothers, Santa Anna, CA) and one
feeding of brine shrimp nauplii, ad libitum.
EDC exposure. Medaka were exposed in
two consecutive experiments. In the first
experiment medaka were exposed to nominal
concentrations of 0, 10, 50, and 100 µg/L
FAD and 0.7 µg/L TBT. This was designed as
a range-finding study to determine potential
masculinizing concentrations of a pharma-
ceutical AI and determine the responsiveness
of the system to an environmental AI. The
second exposure consisted of nominal concen-
trations of 300 µg/L FAD, 1.5 µg/L TBT,
7.5 µg/L DDT, 50 µg/L FAD with 7.5 µg/L
DDT, 300 µg/L FAD with 7.5 µg/L DDT,
and 1.5 µg/L TBT with 7.5 µg/L DDT. DDT
concentrations were selected based on levels
previously shown to induce male-to-female sex
inversion (Kuhl et al. 2005).
Eggs were collected from 15-cm cylindri-
cal ﬁlter sponges used as spawning substrates.
Embryos were transferred to glass hatching
jars containing about 4 L of hatching solution
(1.00 g/L NaCl, 0.030 g/L KCl, 0.040 g/L
CaCl2, 0.162 g/L MgSO4 in distilled water)
with the salinity of the hatching solution
brought to 5 g/L with NaCl to control fun-
gus. Hatching jars were maintained under
continuous ﬂuorescent light in a water bath at
24 ± 1°C and vigorously aerated to suspend
embryos.
At hatch, 75 d-rR fry were housed in
three retention chambers (100-mm Petri dish
bottoms with attached 475-µm nylon collar)
with 25 fish in each chamber. For the first
exposure, fry were exposed to four duplicated
exposure treatments (control, three FAD con-
centrations, and one TBT concentration) for a
total of 8 test aquaria. For the second expo-
sure, fry were exposed to seven duplicated
exposure treatments (control, carrier control,
FAD, two FAD + DDT combinations, TBT,
and TBT + DDT) for a total of 14 test
aquaria. Test aquaria were 35 L with a water
depth of 19 cm maintained by drain siphon.
Test aquaria were housed within a central
water bath kept at 27 ± 1°C and provided
with a 16-hr light/8-hr dark photoperiod sup-
plied by ﬂuorescent bulbs.
Exposure was conducted in a setup similar
to that described by Walker et al. (1985) and
Manning et al. (1999). Brieﬂy, a water parti-
tioner delivered 2 L of test solution each cycle
to splitter/mixing boxes that dispensed 1 L to
each duplicate aquarium. The exposure sys-
tem cycled between three and ﬁve cycles per
hour during the exposure period. Test con-
centrations were prepared each cycle by injec-
tion of appropriate stock to the splitter boxes
of each treatment using Hamilton PSD2 liq-
uid injectors (Hamilton Company, Reno,
NV). Stocks were created by dissolving the
compound in the appropriate solvent. DDT
and TBT were dissolved in triethylene glycol,
and FAD was dissolved in well water.
Water quality (pH, temperature, and dis-
solved oxygen) was measured twice each
week, and water samples were removed four
times (day 0, 5, 8, and 14) for analytical
analysis of the test chemicals. Survival was
monitored and recorded daily, and all dead
fry were removed. Six fish per aquaria
(12/treatment) were sampled, weighed, and
archived for molecular analysis on days 5, 9,
and 14. Six sampled fish per treatment were
preserved in 200 µL RNAlater (Ambion,
Austin, TX) for mRNA analysis, and six were
preserved in 200 µL phosphate buffer
(100 mM KCl, 10 mM KH2PO4, 1 mM
EDTA, 10 mM dithiothreitol, pH 7.4) for
enzyme activity analysis. Upon exposure com-
pletion, fry were transferred to 18.5-L grow-
out aquaria until sexual maturity so secondary
sex characteristics could be observed. After sex
determination, fish were terminally anes-
thetized with MS-222 and discarded.
Real-time quantitative RT-PCR. Ovarian
(cyp19a) and brain aromatase (cyp19b) expres-
sion was measured using real-time quantitative
reverse-transcriptase polymerase chain reaction
(RT-PCR). Due to lack of detection of ovar-
ian aromatase with real-time PCR, further
examination of cyp19a was performed using
multiple primer pair with visualization of
expression using both real-time methods and
2% agarose gel/ethidium bromide. Total RNA
was extracted from whole fry using a Trizol
procedure and puriﬁed with a phenol: chloro-
form extraction followed by an ethanol precip-
itation. Total RNA concentration was
measured using a Beckman (Fullerton, CA)
DU640 spectrophotometer and treated with
DNase H (Invitrogen, Carlsbad, CA) to
remove genomic DNA contamination. cDNA
was synthesized from 1 µg total RNA using
Superscript II reverse transcriptase from
Invitrogen and random decamers. Real-time
PCR was accomplished using Taqman chem-
istry (Heid et al. 1996).
Forward and reverse primers for cyp19a
and cyp19b ampliﬁcation and dual dye-labeled
FAM (6-carboxyfluorescein; excitation,
490 nm; emission, 520 nm)–Black Hole
Quencher (BHQ) were designed from the
ovarian and brain aromatase sequence
(Genebank accession nos. D82968 and
AY319970) using Beacon Designer 3.01
(PREMIER Biosoftware, Palo Alto, CA)
(oligo 1–7) (Table 1). 18S primers designed
from published medaka 18S sequence and
Cy5 (excitation, 596 nm; emission, 615 nm)–
Iowa Black RQ dual-labeled Taqman probes
(Integrated DNA Technologies, Coralville,
IA) were used as internal normalization stan-
dard (oligo 8, 9, 10) (Table 1). Integrated
DNA Technologies supplied probes, and we
used a Bio-Rad (Hercules, CA) IQ-Cycler
real-time PCR system to amplify and measure
fluorescence of aromatase and 18S. For the
reactions in the first exposure, conditions
consisted of 100 nM probe, 900 nM primer
for aromatase, and 100 nM probe and 50 nM
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concentrations were tested to ensure equal
amplification efficiency between aromatase
and 18S.
Due to differences in the ratio of 18S and
aromatase concentrations in fish collected at
each sample period in the second exposure, we
used different concentrations of probe and
primers to obtain equal ampliﬁcation efﬁcien-
cies. Day 5 conditions consisted of 100 nM
probe, 1,200 nM primer for aromatase, and
100 nM probe and 35 nM primers for 18S.
Day 9 conditions were 100 nM probe,
1,200 nM primer for aromatase, and 100 nM
probe and 40 nM primers for 18S. On
day 14, no primer concentrations could be
determined that would express both aromatase
and 18S for all samples in multiplex with
equal amplification efficiency. Therefore,
day 14 samples were measured in separate sin-
gle-plex reactions using Bio-Rad IQ Real-
Time SYBRMix with SYBRGreen. Multiplex
reactions used Bio-Rad IQ Real-Time
Supermix according to manufacturer’s instruc-
tions. Cycle parameters were 50°C for 120 sec,
95°C for 120 sec, 50 cycles of 95°C for 15 sec,
and 61°C for 30 sec. Relative expression was
calculated with the comparative Ct (∆∆Ct)
method, which involves comparing the thresh-
old cycle (Ct) values of the treated samples
with the nontreated controls (calibrator). The
Ct values of both the calibrator and the treated
samples are then normalized to the endoge-
nous housekeeping gene 18S. Gene expression
for each sampling time is expressed as fold
increase over same-day control.
Aromatase activity. Aromatase activity was
measured by a tritiated water release assay
based on the work of Thompson and Siiteri
(1974) as adapted to medaka by Melo and
Ramsdell (2001) and Contractor et al. (2004).
Whole medaka fry sampled during exposure
were homogenized in phosphate buffer (1 M
KCl, 0.01 M K2HPO4, and 0.001 M EDTA,
pH 7.4). Protein concentration of homogen-
ate was determined using a bicinchoninic acid
protein assay kit (Pierce, Rockford, IL).
Homogenate containing about 20 mg of pro-
tein was incubated with 5 nM androst-4-ene-
3,17-dione [1β-3H(N)] (Perkin Elmer,
Boston, MA) in a 200 µL solution of 1 mM
NADPH, 10 mM glucose-6-phosphate,
1 U/mL glucose-6-dehydrogenase, 10 mM
potassium phosphate (dibasic), 1,000 mM
potassium chloride, 1 mM EDTA, and 1 mM
dithiothreitol at 37°C for 3 hr. After incuba-
tion, reactions were terminated by immersion
in ice-cold water and adding 100 µL 30%
trichloroacetic acid, and centrifuged at 1,700g
for 10 min to remove precipitated protein.
Unconverted substrate was removed by vor-
texing vigorously for 60 sec with 1 mL chloro-
form followed by centrifugation at 1,700g for
25 min at 4°C. Addition of a 5% charcoal/
0.5% dextran slurry followed by a 40 sec
vortex and 30 min centrifugation (10,000g)
was used to remove any residual androst-4-
ene-3,17-dione. Radioactivity of tritiated
water was measured in a Beckman LS6500
liquid scintillation counter and background
subtracted using samples without homogen-
ate. Sensitivity of detection was set at two
standard deviations above the mean blank
activity to be considered detectable.
Analytical chemistry. Magnolia Scientiﬁc
Services Inc. (Hattiesburg, MS) measured
o,p´-DDT and TBT. o,p´-DDT was measured
according to U.S. Environmental Protection
Agency (EPA) method 608 (U.S. EPA 1988),
and TBT was measured according to U.S.
EPA method 282.3 (U.S. EPA 1989). 
We determined FAD concentration using
reverse-phase high-pressure liquid chromatog-
raphy (HPLC) with photo diode array detec-
tion. Water samples (~ 5 mL) were collected
twice weekly in glass vials and injected
directly as 1.0 mL aliquots onto a 4.6 mm ×
25 cm Beckman Ultrasphere C18 reverse-
phase column connected to a Beckman Gold
HPLC system. Samples were chromato-
graphed using a gradient program with a
mobile phase starting at 60% methanol/40%
50 mM phosphate buffer (pH 7.0) for 4 min
and increased to 80% methanol/20% buffer
over 2 min, where it was held for 9 min.
Mobile phase was then returned to 60%
methanol/20% phosphate buffer to prepare
the column for the next sample. FAD in col-
umn eluate was detected using a Beckman
System Gold 168 photodiode array detector
set at 229 nm. A five-point standard curve
was developed with FAD dissolved in well
water for sample quantification. Samples
were measured in duplicate in conjunction
with standards. Limit of detection was
approximately 5 µg/L.
Statistical analysis. We compared treat-
ments and controls for percent survival with
the chi-square test after transformation of per-
centages by the arcsine square root procedure.
Deviations from a 1:1 sex ratio were analyzed
by the replicated goodness-of-ﬁt test (G-test)
followed by the unplanned test of the homo-
geneity of replicates. In treatments were no
males remained after exposure, we added 0.05
to values for all males and females for all treat-
ments so that the natural logarithm could be
calculated. Throughout all experiments, each
fish was treated as a replicate for both aro-
matase activity and cyp19b expression (n =6 )
because space for individual experimental units
was limited. We compared cyp19b expression
and aromatase activity among treatments by
one-way analysis of variance (ANOVA). A
Kolmogorov-Smirnov one-sample test was
used to test for normality, and Levine’s test was
used to test for homogeneity of variance. If
data failed either test, the we used the nonpara-
metric Kruskal-Wallis ANOVA to examine
differences. If significant difference among
groups was observed, a Dunn’s multiple com-
parisons test on each day separately was used to
determine where significance occurred.
Statistical signiﬁcance was accepted at p < 0.05.
All statistical analyses and graphing were com-
pleted using Sigmastat 3.1 (Systat Software,
Inc., Point Richmond, CA) and SPSS 11.5
(SPSS, Inc., Chicago, IL). 
Results
Juvenile medaka exposure. In the first expo-
sure, juvenile medaka were exposed in a ﬂow-
through system to FAD and TBT for 2 weeks
beginning at hatch. Measured concentrations
Kuhl and Brouwer
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Table 2. Nominal and actual FAD and TBT exposure concentrations, growout survival, and water quality
parameters.
Nominal Actual Percent Percent survival Temperature
(µg/L) (µg/L ± SE) nominal growout (°C ± SE) pH ± SE DO (mg/L ± SE)
0 — 57 26.7 ± 0.1 8.8 ± 0.03 6.3 ± 0.05
10 FAD 11.29 ± 2.27 113 58 26.7 ± 0.1 8.8 ± 0.02 6.5 ± 0.05
50 FAD 60.25 ± 0.5 121 63 26.7 ± 0.1 8.7 ± 0.04 6.2 ± 0.05
100 FAD 141.3 ± 5.81 141 52 26.8 ± 0.1 8.7 ± 0.02 6.3 ± 0.04
0.7 TBT 0.63 ± 0.007 90 51 26.7 ± 0.1 8.7 ± 0.04 6.3 ± 0.05
DO, dissolved oxygen. 
Table 1. Oligonucleotide sequence for real-time PCR primers and probes. 
Oligo Sequence Location Function
1 AGAAGAAAACCATCCCTGGAC 208–229 cyp19a forward 1
2 CCATTTCCTTCCTCTTTCGCT 847–868 cyp19a reverse 1
3 ACTGTAGGACTCCCATCCG 120–139 cyp19a forward 2
4 TCTTCTCACTGTGACTCCAGA 193–214 cyp19a reverse 2
5 CTGCACCCTGAACAGCATCAG 94–115 cyp19b forward
6 AGTAGAGGGCTATCACAAAATCTC 171–192 cyp19b reverse
7 FAM-CCTGTCTCAGCAGCCTGTGGA-BHQ 126–152 cyp19b probe
8 GTTATTCCCATGACCCGCCG 1,445–1,465 18S forward
9 TTCCCGTGTTGAGTCAAATTAAGC 1,344–1,363 18S reverse
10 Cy5-ACTCCTGGTGGTGCCCTTCCGT-BHQ 1,400–1,425 18S probeof the test chemicals were approximately
90–141% of nominal concentrations. Survival
ranged from 51 to 63%, and according to the
goodness-of-ﬁt chi-square test, no signiﬁcant
difference in survival between controls and
exposed groups existed (Table 2). Develop-
mental exposure to FAD and TBT did not
signiﬁcantly alter adult sex ratios at concentra-
tions chosen. In d-rR medaka, white males and
red females indicate a phenotypic sex inversion.
At this exposure, there were no sex inversions
as evidenced by the lack of any white males or
red females (Table 3).
In the second exposure, medaka were
exposed to FAD, TBT, and o,p´-DDT for
2 weeks beginning at hatch. Measured doses
ranged between 81 and 101% of nominal
concentrations. Survival ranged from 39 to
50%, and there was no signiﬁcant difference
in survival between controls and exposed
groups (Table 4). According to a goodness-of-
fit G-test, developmental exposure to FAD
and TBT did not alter sex distributions or
induce sex inversion. However, o,p´-DDT
significantly altered sex distributions in all
o,p´-DDT exposures regardless of inhibitor
cotreatment (Table 5).
Aromatase expression. Gene expression
was measured in individual whole fry on
days 5, 9, and 14 for each treatment and
quantitated using the ∆∆Ct method. 18S was
used as the internal normalization standard,
and expression data for each time point are
expressed as fold change relative to the mean
of the same-day controls. Ovarian aromatase
was not detected in any sample through
measurement with real-time PCR or tradi-
tional PCR. Further multiple primer sets were
tested in multiple conditions (data not
shown). Therefore, all following data repre-
sent brain aromatase expression.
In the ﬁrst exposure, day 9 samples were
lost because of defective extraction reagent. A
Kruskal-Wallis ANOVA demonstrated that
brain aromatase expression levels showed a
signiﬁcant decrease in the TBT treatment ver-
sus control treatment at sampling day 5
(Figure 1). However, this signiﬁcance was lost
by sampling day 14 (data not shown).
In the second exposure, the day 14 sam-
pling period demonstrated a signiﬁcant differ-
ence in cyp19b expression between treatments
according to a Kruskal-Wallis ANOVA.
Pairwise multiple comparisons between treat-
ments revealed that this difference is between
FAD- and TBT-only treatments and DDT
only (Dunn’s method, p < 0.05). Fish
exposed to FAD- and TBT-only treatments
also had lower expression levels than those
exposed to the AI and o,p´-DDT cotreat-
ments; however, these differences are not sig-
niﬁcant (Figure 2). Day 5 and day 9 sampling
periods show similar trends but are not signif-
icant (results not shown).
Aromatase activity. Aromatase activity
was measured using a tritiated water release
assay. In the first exposure, assay sensitivity
was 1.49, 1.20, and 0.86 fmol/hr/mg protein
for sampling days 5, 9, and 14, respectively.
The highest concentration of FAD and TBT
treatment levels consistently resulted in aro-
matase activity levels below level of sensitivity
for this assay and can be considered non-
detectable (Figure 3).
In the ﬁrst experiment, changes in activity
followed the same pattern as changes in gene
expression on all sampling days, with decreas-
ing activity at increasing concentrations of
FAD and in the TBT treatment. Although
day 5 and day 9 showed no signiﬁcant differ-
ence between any treatments (results not
shown), day 14 showed a signiﬁcant decrease
in activity between the controls and the highest
concentrations of FAD and TBT (Figure 3).
For the second exposure, the limit of detec-
tion (LOD) was 2.30, 1.37, and 0.26 fmol/
hr/mg protein for days 5, 9, and 14, respec-
tively. Only the control treatment had measur-
able levels of aromatase activity on day 5, and
all day 9 samples were < LOD. On day 14,
only the o,p´-DDT/high FAD and o,p´-DDT/
TBT cotreatments had enzyme activity levels
below assay sensitivity (Figure 4).
Aromatase activity demonstrated a pattern
different from aromatase expression. Unlike
cyp19b expression data, which showed an
increase in aromatase expression in all
o,p´-DDT treatments regardless of presence
of inhibitors, aromatase activity showed an
increase only in the o,p´-DDT control treat-
ment (Figure 4). A Kruskal-Wallis test
demonstrated a significant difference in aro-
matase activity between treatments on day 14.
Pairwise multiple comparison procedure
revealed that the o,p´-DDT–only treatment is
significantly different from all other treat-
ments. The cotreatments of o,p´-DDT and
AIs had reduced or nondetectable aromatase
activity with no corresponding decrease in
aromatase gene expression. However, this
decrease in activity was not significant. This
trend was not observed on sampling day 5 or
day 9 (results not shown).
Discussion
Most laboratory research to date on EDCs has
focused on the effects of a single compound
on an organism. However, in the environ-
ment, organisms are exposed to complex mix-
tures of potentially synergistic and antagonistic
compounds, and it is unknown how these
chemicals interact in vivo and whether such
interactions diminish or exacerbate their indi-
vidual effects on the health of the organism.
To begin addressing these questions, our
objectives in the present study were 2-fold: to
examine the role of brain aromatase in
o,p´-DDT–induced sex reversal in medaka
and to determine if an environmentally rele-
vant mixture of both estrogenic (o,p´-DDT)
Brain aromatase and sex reversal in EDC mixtures
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Table 3. Sex and color at sexual maturity after FAD and TBT treatments.
Treatment Red genotypic male White phenotypic male White genotypic female Red phenotypic female
Control 32 0 35 0
11.3 FAD 35 0 34 0
60.3 FAD 36 0 38 0
141 FAD 27 0 34 0
0.63 TBT 28 0 32 0
Table 4. Nominal and actual FAD, TBT, and DDT exposure concentrations with growout survival. 
Nominal Actual TBT Actual FAD Actual o,p´-DDT Percent survival
Treatment (µg/L) (µg/L ± SE) (µg/L ± SE) (µg/L ± SE) growout
TEG control 0 — — — 40
FAD 300 — 243 ± 6.7 — 40
TBT 1.5 1.52 ± 0.03 — — 44
DDT 7.5 — — 7.48 ± 0.04 38
DDT + low FAD 7.5 + 50 — 49.75 ± 11.6 7.42 ± 0.05 40
DDT + high FAD 7.5 + 300 — 270 ± 7.6 7.49 ± 0.04 50
DDT + TBT 7.5 + 1.5 1.40 ± 0.03 — 7.53 ± 0.08 39
Abbreviations: —, not applicable; TEG, triethylene glycol. 
Table 5. Sex and color at sexual maturity in o,p´-DDT/FAD and o,p´-DDT/TBT cotreatments. 
Treatment Red genotypic male White phenotypic male White genotypic female Red phenotypic female
TEG control 24 0 23 0
FAD 18 0 28 0
TBT 26 0 24 0
DDT 0 0 21 22
DDT + low FAD 0 0 26 20
DDT + high FAD 0 0 33 25
DDT + TBT 0 0 25 19
TEG, triethylene glycol.and apparent antiestrogenic (TBT) chemicals,
which have opposing effects on aromatase
activity, can block each other’s effects on
reproductive development. Extensive experi-
ments showed that ovarian aromatase tran-
scripts could not be detected in medaka fry
(0–14 dph) by real-time or traditional
RT-PCR. Further, ovarian aromatase could
not be detected upon stimulation of the estro-
gen response system after exposure to estradiol
and o,p´-DDT. It appears, therefore, that the
brain isoform of aromatase accounts for most,
if not all, estradiol production during this life
stage of the medaka and that the aromatase
activity measured in this study represents the
brain form of this enzyme.
To accomplish our stated objectives, we
exposed juvenile medaka to an environmental
estrogen in the presence and absence of two
AIs and examined the effects on aromatase
expression and activity and sex reversal. After a
2-week exposure, all ﬁsh developed female sec-
ondary sex characteristics regardless of the pres-
ence of AIs and independent of levels of brain
aromatase activity, indicating that an increase
in brain aromatase activity, as observed with
o,p´-DDT exposure only, is not required for a
male-to-female sex reversal resulting from
exposure to an environmental estrogen. The
results of the study presented here also show
that the effects (feminization) of an environ-
mental estrogen (o,p´-DDT) are not negated
by the antagonistic effects of an environmental
antiestrogen (TBT) at the exposure conditions
and developmental stage examined. Whether
the results of this specific case are of general
validity for mixtures with predicted antagonis-
tic effects deserves further study.
Additionally, results from this study
demonstrate that immersion exposure to AIs
alone did not result in any female-to-male
inversions, even though aromatase activity was
inhibited. These results contrast with several
published studies in which inhibition of aro-
matase by both pharmaceutical (FAD) and
environmental (TBT) AI exposure (McAllister
and Kime 2003; Uchida et al. 2004) can result
in masculinization of several fish species,
including Japanese flounder, zebrafish, and
salmon (Kitano et al. 2000; Kwon et al. 2000;
Piferrer et al. 1993; Uchida et al. 2004).
Masculinization occurs concomitantly with a
decrease in aromatase expression, suggesting
that manipulation of the aromatase system
during development can alter gonadal differ-
entiation (Fenske and Segner 2004).
These studies on the role of aromatase in
sex reversal during development support the
theory that androgens and estrogens are the
natural sex inducers in fish and play pivotal
roles in sex differentiation (Devlin and
Nagahama 2002). Other evidence such as sex-
ually dimorphic expression of aromatase in
developing zebrafish (Trant et al. 2001) and
the ability of exogenous steroid treatment to
influence sex differentiation (Yamamoto
1958) suggest the importance of sex steroid
production in the very early steps in gonad
differentiation. Also, in medaka, inhibition of
aromatase can result in the prevention of ovar-
ian cavity formation, suggesting the impor-
tance of endogenous estrogen in gonadal
development (Suzuki et al. 2004). 
However, other evidence exists that suggests
sex steroids may not play such an important
role. For example, in medaka, germ cell differ-
entiation appears to occur before somatic
steroid-producing cells are observed (Satoh
1974). Further, in a study by Kawahara and
Yamashita (2000), medaka eggs incubated with
an AI resulted in no abnormal sex ratios. From
these observations, the authors concluded that
female sex determination in medaka is not
estrogen dependent. They also suggested that
estrogen-independent activation of the estrogen
receptor may be a primary pathway in female
gonadal development. They emphasized that
the observations of female-to-male sex inversion
after treatment with AI in other vertebrates and
ﬁsh suggests a role of aromatase only during the
sex determination period and not the impor-
tance of estrogen and aromatase as the natural
sex inducer in gonadal differentiation.
In the present study, exposure to AIs sig-
niﬁcantly reduced aromatase activity between
days 9 and 14 yet did not induce a sex inver-
sion. This could be because male sex differenti-
ation is irreversibly determined before day 9.
However, it is more likely that our treatment
period terminated too early, because male germ
cell proliferation does not occur until 14 dph
(Satoh 1974). Sensitivity of sex differentiation
to endocrine disruptors has been shown to be
dependent on duration and dose of exposure
and on developmental stage. Insufﬁcient expo-
sure length or dosage concentrations can result
in lack of response (Cheek et al. 2001b). The
lack of response to aromatase inhibition
reported by Kawahara and Yamashita (2000)
may therefore be due to the developmental
period of exposure. In most cases, the most
sensitive period is just before or at the same
time as histologic differentiation of the primi-
tive gonad (Hunter and Donaldson 1983). In
medaka, differentiation occurs at hatch, with
the proliferation of ovarian cells beginning
shortly after hatch (about 6–10 dph) (Satoh
1974). Medaka have been shown to be sensi-
tive to feminization by estradiol during this
proliferation period (Cheek et al. 2001a;
Nimrod and Benson 1998). Unlike female
germ cells, male germ cells cease to divide
Kuhl and Brouwer
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Figure 1. Effects of FAD and TBT on brain aro-
matase expression on day 5 shown as fold change
relative to same-day control as measured by real-
time PCR (mean ± SE). 
*Signiﬁcant difference (p < 0.05). 
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Figure 2. Effects of FAD, TBT, and o,p´-DDT, as well
as FAD/DDT and TBT/DDT coexposure, on brain aro-
matase expression on day 14 shown as fold change
(± SE) relative to same-day control as measured by
real-time PCR. Bars with different letters are signiﬁ-
cantly different from each other based on Dunn’s
multiple comparison test (p < 0.05). 
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Figure 3. Effects of FAD and TBT exposure on aro-
matase enzyme activity (mean± SE, fmol/hr/mg pro-
tein) on day 14. Values for 141.3 FAD and 0.631 TBT
were < LOD. 
*Signiﬁcant difference (p < 0.05). 
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Figure 4. Effects of FAD, TBT, o,p´-DDT, FAD/DDT,
and TBT/DDT on aromatase enzyme activity (mean
± SE, fmol/hr/mg protein) on day 14. Bars with dif-
ferent letters are significantly different from each
other (p < 0.05). immediately after hatching, and proliferation is
delayed until about the 9–10 mm larval stage
(about 14–20 dph) (Satoh 1974). This is also
the stage of development in which male gonial
cells first appear in the female gonad upon
androgen treatment (Kobayashi and Hishida
1985). Thus, lack of masculinization in
response to aromatase inhibition observed in
this study might be due to termination of expo-
sure before male germ cell proliferation begins.
In the present study, the inhibition of aro-
matase did not induce a female-to-male inver-
sion, i nor did it prevent a male-to-female
inversion induced by o,p´-DDT. Several stud-
ies have demonstrated a correlation between an
increase in aromatase expression and activity
upon exposure to environmental estrogens and
sex differentiation in ﬁsh (Chiang et al. 2001;
Fenske and Senger 2004; Kitano et al. 2000;
Scholz and Gutzeit 2000; Tanaka et al. 1995).
Previous work in this laboratory (Kuhl et al.
2005) also demonstrated the importance of the
aromatase system in ﬁsh gonadal development
by observing a significant 5-fold increases in
aromatase expression and activity at o,p´-DDT
concentrations that induce a male-to-female
sex inversion. 
Results from the present study, however,
demonstrate that sex inversion can be induced
without a corresponding increase in aro-
matase activity. Treatment with o,p´-DDT
alone induces both aromatase activity and
brain aromatase expression, while resulting in
a complete male-to-female sex inversion.
However, inhibition of aromatase activity in
o,p´-DDT/AI–cotreated fish also results in a
complete male-to-female sex inversion. In
these fish, there is an increase in brain aro-
matase expression while activity is reduced to
nondetectable levels. Altered aromatase activ-
ity levels are therefore not a requirement for
sex inversion in ﬁsh.
The apparent lack of aromatase involve-
ment suggests that alternative, non-aromatase-
dependent pathways exist through which
o,p´-DDT may bring about sex reversal. For
example, exogenous estrogen treatment can also
result in reduction of expression of several
steroidogenic enzymes, including P450c17,
3βHSD, and P45011β in the differentiating
testis (Govoroun et al. 2001). This would
decrease the synthesis of 11-oxygenated andro-
gen and may be an important step in exogenous
estrogen feminization. Further, xenobiotics can
induce steroid-metabolizing enzymes, including
steroid sulfotransferases, steroid glucuronida-
tion enzymes, and steroid hydroxylases (You
2004). Because the ratio of androgens to estro-
gens may be more important in differentiating
gonads than their absolute values (Bogart
1987), xenobiotic alterations of androgen levels
may also play a role in the cotreatments con-
ducted in this study. Steroidogenic enzyme lev-
els and androgen to estrogen ratios during
cotreatments must be measured to examine the
possibility of this mechanism. Finally, non-
genomic actions mediated through membrane-
bound hormone receptors also can influence
steroid production. Loomis and Thomas
(2000) demonstrated that estrogens, and likely
xenoestrogens including o,p´-DDT, can cause a
decrease in gonadotropin-stimulated androgen
production through a nongenomic mechanism
in the Atlantic croaker (Micropogonias undula-
tus). This may further interfere with steroid
production and the ratios between androgens
and estrogens.
In conclusion, the present study demon-
strates that the xenoestrogen o,p´-DDT
increases brain aromatase activity accompa-
nied by complete male-to-female sex inver-
sion. Coexposure to o,p´-DDT and AIs does
suppress aromatase activity but does not pre-
vent sex reversal. Thus, increased aromatase
activity is not necessary for sex inversion, and
alternatively, aromatase-independent pathways
for sex reversal resulting from xenobiotic treat-
ment must exist. This study shows that expo-
sure to AIs during days 0–14 fails to induce
female-to-male sex inversion. This suggests
that testis differentiation in d-rR medaka does
not occur until after 14 dph. The observation
that exposure to a mixture of estrogenic and
antiestrogenic compounds does not block
estrogen-induced sex reversal suggests that, in
the environment, exposure to antagonistic
EDCs may not necessarily lessen the harmful
impacts of these compounds.
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